WO2024052542A3 - A peptide cocktail - Google Patents
A peptide cocktail Download PDFInfo
- Publication number
- WO2024052542A3 WO2024052542A3 PCT/EP2023/074755 EP2023074755W WO2024052542A3 WO 2024052542 A3 WO2024052542 A3 WO 2024052542A3 EP 2023074755 W EP2023074755 W EP 2023074755W WO 2024052542 A3 WO2024052542 A3 WO 2024052542A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- immunogenic fragment
- inducing
- immune response
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 239000012634 fragment Substances 0.000 abstract 6
- 230000002163 immunogen Effects 0.000 abstract 6
- 102000008300 Mutant Proteins Human genes 0.000 abstract 4
- 108010021466 Mutant Proteins Proteins 0.000 abstract 4
- 230000037433 frameshift Effects 0.000 abstract 4
- 230000028993 immune response Effects 0.000 abstract 4
- 230000001939 inductive effect Effects 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 101000923332 Homo sapiens Protein asteroid homolog 1 Proteins 0.000 abstract 1
- 102100032661 Protein asteroid homolog 1 Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
There is disclosed a peptide mixture comprising a first, second and third peptide. The first peptide is capable of inducing an immune response against a TGFβR2 -1a frameshift mutant protein, wherein the first peptide comprises i) an immunogenic fragment of SEQ ID NO: 3, wherein the immunogenic fragment comprises at least 8 consecutive amino acids of SEQ ID NO: 3 including at least one of positions 121 and 135 of SEQ ID NO: 3, or ii) an immunogenic fragment of SEQ ID NO: 2, wherein the immunogenic fragment comprises at least 8 consecutive amino acids of SEQ ID NO: 8. The second peptide is capable of inducing an immune response against a ASTE1 -1a frameshift mutant protein, wherein the second peptide comprises an immunogenic fragment of SEQ ID NO: 5, wherein the immunogenic fragment comprises at least 8 consecutive amino acids of SEQ ID NO: 19. The third peptide is capable of inducing an immune response against a TAF1β -1a frameshift mutant protein, wherein the third peptide comprises the amino acid sequence of SEQ ID NO: 21. There is also disclosed a peptide capable of inducing an immune response against a TAF1β -1a frameshift mutant protein, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 21.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU502776 | 2022-09-09 | ||
| LU502776 | 2022-09-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2024052542A2 WO2024052542A2 (en) | 2024-03-14 |
| WO2024052542A3 true WO2024052542A3 (en) | 2024-04-18 |
Family
ID=83193499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2023/074755 WO2024052542A2 (en) | 2022-09-09 | 2023-09-08 | A peptide cocktail |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024052542A2 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999058552A2 (en) * | 1998-05-08 | 1999-11-18 | Norsk Hydro Asa | Peptides that ellicit t, cellular immunity |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| JP2016028025A (en) * | 2015-07-29 | 2016-02-25 | ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer |
| WO2018223093A1 (en) * | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Universal cancer vaccines and methods of making and using same |
| WO2020097184A1 (en) * | 2018-11-06 | 2020-05-14 | Icahn School Of Medicine At Mount Sinai | Peptides, compositions and vaccines for treatment of microsatellite instability hypermutated tumors and methods of use thereof |
| WO2020239937A1 (en) * | 2019-05-29 | 2020-12-03 | Hubro Therapeutics As | Peptides |
| WO2021239980A2 (en) * | 2020-05-28 | 2021-12-02 | Hubro Therapeutics As | A peptide cocktail |
-
2023
- 2023-09-08 WO PCT/EP2023/074755 patent/WO2024052542A2/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999058552A2 (en) * | 1998-05-08 | 1999-11-18 | Norsk Hydro Asa | Peptides that ellicit t, cellular immunity |
| WO2003087162A2 (en) * | 2002-04-18 | 2003-10-23 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| JP2016028025A (en) * | 2015-07-29 | 2016-02-25 | ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ | Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer |
| WO2018223093A1 (en) * | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Universal cancer vaccines and methods of making and using same |
| WO2020097184A1 (en) * | 2018-11-06 | 2020-05-14 | Icahn School Of Medicine At Mount Sinai | Peptides, compositions and vaccines for treatment of microsatellite instability hypermutated tumors and methods of use thereof |
| WO2020239937A1 (en) * | 2019-05-29 | 2020-12-03 | Hubro Therapeutics As | Peptides |
| WO2021239980A2 (en) * | 2020-05-28 | 2021-12-02 | Hubro Therapeutics As | A peptide cocktail |
Non-Patent Citations (2)
| Title |
|---|
| P. MABY ET AL: "Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy", CANCER RESEARCH, vol. 75, no. 17, 1 September 2015 (2015-09-01), US, pages 3446 - 3455, XP055636602, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-14-3051 * |
| WESTDORP HARM ET AL: "Opportunities for immunotherapy in microsatellite instable colorectal cancer", CANCER IMMUNOLOGY IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 65, no. 10, 8 April 2016 (2016-04-08), pages 1249 - 1259, XP036063227, ISSN: 0340-7004, [retrieved on 20160408], DOI: 10.1007/S00262-016-1832-7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024052542A2 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1353295A (en) | Peptides derived from a retrovirus of the HIV group, and their use | |
| HUP9901186A2 (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
| EP1591529A3 (en) | Human CLTA-8 and uses of CTLA-8-related proteins | |
| EP2258383A3 (en) | Antigenic peptides derived from telomerase | |
| IL152625A (en) | SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID b FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID b AND AMYLOID DEPOSITS | |
| WO1999058564B1 (en) | Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use | |
| EP1420821B8 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
| WO2021239980A9 (en) | A peptide cocktail | |
| EP4276463A3 (en) | Peptides | |
| US5338668A (en) | Opioid peptides derived from wheat proteins | |
| Kageyama et al. | Isolation of an activation intermediate and determination of the amino acid sequence of the activation segment of human pepsinogen A | |
| CA2380833A1 (en) | Proteins derived from white spot syndrome virus and uses thereof | |
| EP2314604A3 (en) | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof | |
| EP0976402A3 (en) | Vaccines for prevention of gram-negative bacterial infections and endotoxin-related diseases | |
| WO2002101052A3 (en) | Salutaridinol 7-o-acetyltransferase and derivatives thereof | |
| AU2002307510A1 (en) | Cytokine protein family | |
| WO2002068608A3 (en) | Sulfated ccr5 peptides for hiv-1 infection | |
| WO2024052542A3 (en) | A peptide cocktail | |
| WO2004014937A3 (en) | Thrombin peptide derivatives | |
| WO2003090667A3 (en) | Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| AU585167B2 (en) | Novel substrate peptides | |
| Abubakar et al. | New Derivation of the Inhibitory Activity against Angiotensin Converting Enzyrne (ACE) from Sweet Cheese Whey | |
| AU3283199A (en) | Novel peptide diagnostic reagent and kit for detection of rickettsiosis | |
| CA2057612A1 (en) | Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23768532 Country of ref document: EP Kind code of ref document: A2 |